Cingulate Inc.

FRC's fair value estimate for Cingulate Inc., and the rating behind it. CING last traded at $5.02; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Valuation, profitability, liquidity and leverage ratios for Cingulate Inc.. Starting points for Cingulate Inc.: EPS -$5.30, beta -0.89 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend history, yield and payout sustainability for Cingulate Inc.. Cingulate Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Reported vs. expected earnings history for Cingulate Inc.. Trailing twelve-month EPS for Cingulate Inc. stands at -$5.30. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Income statement, balance sheet and cash flow history for Cingulate Inc.. Cingulate Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Cingulate Inc. valued side by side against its closest peers. Cingulate Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Which institutions hold Cingulate Inc., and how their positions are changing. At a $67.6M market value, institutional positions materially move Cingulate Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Buying and selling by Cingulate Inc. executives and directors. Shares of Cingulate Inc. have traded between $3.20 and $6.01 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

U.S. Senate disclosures naming Cingulate Inc.. Cingulate Inc. is a $67.6M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

U.S. House of Representatives disclosures naming Cingulate Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

Latest headlines and company announcements for Cingulate Inc.. Coverage tracks Cingulate Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.